ライフサイエンスコーパス: inefficacy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 clusive; or indicates either serious risk or inefficacy.

2 hree dimensions of exhaustion, cynicism, and inefficacy.

3 (mostly owing to clinical efficacy [38.2%], inefficacy [26.5%], and ADRs [22.8%]).

4 most common reasons for discontinuation were inefficacy (30%), gastrointestinal symptoms (29%), medic

5 (5.1% versus 8.8%, respectively), or due to inefficacy (5.1% versus 11.7%, respectively).

6 tion of all ISDs owing to clinical efficacy, inefficacy, adverse drug reaction (ADR), and other medic

7 s pathway after discontinuing phase 1 due to inefficacy; all other patients received another second-g

8 atients stopped taking the first drug due to inefficacy and 1,023 stopped the first drug due to toxic

9 t cause for ISD discontinuation, followed by inefficacy and ADRs.

10 rican Americans, whereas perceived treatment inefficacy and lacking trust in physicians were associat

11 Relaxin is contraindicated due to inefficacy and severe renal side effects on discontinuat

12 To overcome the inefficacy and undesirable side effects of current cance

13 n low drug accumulation at the tumor region (inefficacy) and drug-induced severe side effects (toxici

14 nt recommendations by authors, study-defined inefficacies, cognitive and depressive symptoms, discont

15 59 (10.6%) patients; only three events (drug inefficacy, gastritis, and reflux esophagitis) in two pa

16 d rate of second drug discontinuation due to inefficacy (hazard ratio [HR] 2.7, 95% confidence interv

17 to toxicity (HR 2.3, 95% CI 1.9-2.9) but not inefficacy (HR 1.2, 95% CI 0.8-1.6).

18 sion rates that correlate with the vaccine's inefficacy in developing regions.

19 Conventional therapy shows inefficacy in most cases and thus development of new the

20 ure and function, which may underlie vaccine inefficacy in the developing world.

21 were high (41-59%) and were more common for inefficacy in the placebo patients (71.4%), whereas they

22 nued their previous antipsychotic because of inefficacy (N=184), olanzapine was more effective than q

23 Further experiments indicate that the inefficacy of antibiotics against coinfection is attribu

24 Considering the inefficacy of available treatments, we propose that dise

25 s substantial ATP equivalents, and (iii) the inefficacy of azole drugs against P. carinii can be expl

26 nhibits Top1mt religation in contrast to the inefficacy of camptothecin on Top1mt.

27 resistance, new pathogens, and the relative inefficacy of current therapy in compromised hosts.

28 instay of arrhythmia treatment; however, the inefficacy of drug treatment and the potential that anti

29 lying mechanisms for the clinically observed inefficacy of glucocorticoids.

30 nexpected practical consequences such as the inefficacy of many MHC class II tetramers in detecting s

31 y of the resistant subpopulation, leading to inefficacy of subsequent colistin therapy.

32 rowing tumor cells contribute to an eventual inefficacy of therapeutic vaccinations.

33 o treatment, dropouts for any reason and for inefficacy of treatment, and important adverse events.

34 atment, study dropout for any reason and for inefficacy of treatment, use of drugs to treat parkinson

35 ation of treatment because of any cause, and inefficacies or intolerabilities.

36 o patient withdrew from the study because of inefficacy or an adverse event related to pramipexole.

37 scontinued their assigned treatment owing to inefficacy or intolerable side effects or for other reas

38 TNF) drugs do not respond because of primary inefficacy or loss of response.

39 In drug therapy, we face the problems of inefficacy or nonspecific effects; hence, nanosystems ar

40 isk of stopping and the reason for stopping (inefficacy or toxicity).

41 rosis factor (anti-TNF) agent, due to either inefficacy or toxicity, are frequently switched to a sec

42 First drug discontinuation due to inefficacy was associated with an increased rate of seco

43 from criss-cross experiments, the functional inefficacy was not rooted in NOD Tregs, which suppressed

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。